Brief: Voyager Therapeutics Q2 EPS USD -0.57

Voyager Therapeutics

06/08/2025 21:01

Overview

Voyager Q2 collaboration revenue falls sharply yr/yr, driven by Neurocrine agreements

Co extends cash runway into 2028, supporting multiple clinical data read-outs

Voyager adds APOE program to Alzheimer's pipeline, expanding franchise

Outlook

Voyager expects cash runway to extend into 2028

Result Drivers

NEUROCRINE PARTNERSHIP - Collaboration revenue decrease due to lower revenue recognized under Neurocrine collaboration

CASH RUNWAY - Co extended cash runway into 2028 through restructuring and cost savings, enabling focus on clinical data

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Collaboration Revenue
$5.20 mln
Q2 EPS
-$0.57
Q2 Net Income
-$33.38 mln
Q2 Basic EPS
-$0.57
Q2 Operating Income
-$36.62 mln
Q2 Pretax Profit
-$33.37 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 12 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Voyager Therapeutics Inc is $15.00, about 77.5% above its August 5 closing price of $3.38

Press Release: ID:nGNXH1gFs

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)